Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 115-121

  Wallis, Robert M ^a  

^a PFIZER INC   (United States)

Author keywords

Clinical; Concordance; Non clinical; QT interval; Repolarization; Ventricular arrhythmias

Indexed keywords

BIOLOGICAL MARKER;

CORRELATION ANALYSIS; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; REPOLARIZATION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; TORSADE DES POINTES;

ANIMALS; DEATH, SUDDEN; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 74549140187     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00395.x     Document Type: Review

References (23)

1. Ando K, Hombo T, Kanno A, Ikeda H, Imaizumi M, Shimizu N et al. (2005). QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99 : 487 500. (Pubitemid 44618149)
2. Berger E, Patel K, Anwar S, Davies W, Sheridan DJ (2005). Investigation of the effects of physiological and vasodilator-induced autonomic activation on the QTc interval in healthy male subjects. Br J Clin Pharmacol 60 : 17 23.
3. Cavero I (2007). Using pharmacokinetic-pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the safety pharmacology society. Expert Opin Drug Saf 6 : 465 471.
4. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54 : 695 703.
5. De Bruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM (2005). Anti-hERG activity and the risk of drug-induced arrhythmias and sudden death. Europ Heart J 26 : 590 597.
6. De Cicco M, Macor F, Robieux I, Zanette G, Fantin D, Fabiani F et al. (1999). Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. Critical Care Med 27 : 332 329.
7. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N (2002). Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Safety 25 : 263 286.
8. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54 : 116 129.
9. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR et al. (2004). A randomised evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24 : 62 69.
10. Hayashi S, Kii Y, Tabo M, Fukuda H, Itoh T, Shimosato T et al. (2005). QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 99 : 423 437. (Pubitemid 44618144)
11. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN (2005). A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 77 : 572 582.
12. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H et al. (2008). Alfuzosin delays cardiac repolarisation through a novel mechanism. J Pharmacol Exp Ther 324 : 427 433.
13. Minematsu T, Ohtani H, Sato H, Iga T (1999). Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci 65 : 197 202.
14. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264 : 2788 2790.
15. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA et al. (2004). Evaluation of vardenafil and sildenafil on cardiac repolarisation. Am J Cardiol 93 : 1378 1383.
16. Ollerstam A, Visser S, Persson AH, Eklund G, Nilsson LB, Forsberg T et al. (2006). Pharmacokinetic-pharmacodynamic modelling of drug-induced effect on the QT interval in conscious telemetered dogs. J Pharmacol Toxicol Methods 53 : 174 183.
17. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 : 32 45.
18. Sager P (2008). Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br J Pharmacol 154 : 1544 1549.
19. KR potassium channel. Cell 81 : 299 307.
20. Stanfield PJ, Sutcliffe MJ, Mitcheson JS (2006). Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Expert Opin Drug Metab Toxicol 2 : 81 94.
21. Toyoshima S, Kanno A, Kitayama T, Sekiya K, Nakai K, Haruna M et al. (2005). QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 99 : 459 471. (Pubitemid 44618147)
22. Wang J, Della PK, Wang H, Karczewski J, Connolly TM, Koblan KS et al. (2003). Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284 : 257 267.
23. Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5 : 116 126.